ISHL HL Update 2021 | Nodular lymphocyte-predominant Hodgkin lymphoma
Dennis Eichenauer
• 15 Mar 2021
Dennis Eichenauer, MD, University Hospital of Cologne, Cologne, Germany, discusses nodular lymphocyte-predominant Hodgkin lymphoma (HL), a rare subtype of HL that accounts for around 5% of all cases, and presents with distinct pathological and clinical characteristics. Dr Eichenauer touches on differences in treatment and progression of nodular lymphocyte-predominant HL in comparison to classical HL and provides an overview of the treatment approach for this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
